Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Non Operating Income (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Non Operating Income for 10 consecutive years, with -$934000.0 as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 79.88% to -$934000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.0 million through Dec 2025, up 120.0% year-over-year, with the annual reading at $1.0 million for FY2025, 120.0% up from the prior year.
  • Non Operating Income for Q4 2025 was -$934000.0 at Ultragenyx Pharmaceutical, up from -$1.0 million in the prior quarter.
  • The five-year high for Non Operating Income was $3.1 million in Q3 2024, with the low at -$4.6 million in Q4 2024.
  • Average Non Operating Income over 5 years is -$412650.0, with a median of -$557000.0 recorded in 2021.
  • The sharpest move saw Non Operating Income plummeted 1288.06% in 2022, then surged 666.67% in 2023.
  • Over 5 years, Non Operating Income stood at -$410000.0 in 2021, then surged by 143.9% to $180000.0 in 2022, then soared by 666.67% to $1.4 million in 2023, then plummeted by 436.45% to -$4.6 million in 2024, then surged by 79.88% to -$934000.0 in 2025.
  • According to Business Quant data, Non Operating Income over the past three periods came in at -$934000.0, -$1.0 million, and $2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.